Eve	Everolimus,
mTOR	mammalian target of Rapamicin,
NET	neuroendocrine tumor,
RR	response rate,
PFS	progression free survival,
OS	overall survival,
NENs	neuroendocrine neoplasms,
WHO	World Health Organization,
GEP	gastro-entero-pancreatic,
NECs	neuroendocrine carcinomas,
FKBP-12	FK506 binding protein-12,
mLST-8	mammalian lethal with SEC13 protein 8,
mTORC-1 and 2	mammalian target of Rapamicin Complex 1 and 2,
mSin-1	mammalian stress-activated protein kinase interacting protein 1
S6K	ribosomal protein S6 kinase,
4EBP1	eukaryotic initiation factor 4E-binding protein 1,
IGF-1	insulin growth factor 1,
IRS-1	insulin receptor substrate 1,
Myc	myelocytomatosis oncogene cellular homolog,
HIF-1	Hypoxia inducible factor 1,
pNETs	pancreatic neuroendocrine tumors,
DAB	3’-3-diaminobenzidine,
RECIST	response evaluation criteria in solid tumors,
SSA	somatostatin analog,
TACE	transarterial chemoembolization,
TSC-1 and 2	tuberous sclerosis complex 1 and 2,
PTEN	phosphatase and tensin homolog,
PI3K	Phosphatidylinositol 3-kinase
SLE	Systemic Lupus Erytematosus